{
  "trial_id": "NCT01874431",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, fasting glucose levels, 2-hour plasma glucose levels, glycated hemoglobin (HbA1c) levels, urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum potassium levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), presence of heart failure with reduced ejection fraction (HFrEF), concomitant medications, history of dialysis for acute renal failure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Baseline UACR",
          "urinary albumin-to-creatinine ratio (UACR)"
        ],
        [
          "Baseline potassium",
          "serum potassium levels"
        ],
        [
          "Baseline eGFR",
          "estimated glomerular filtration rate (eGFR)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Baseline KDQOL-36 domain score (Effects of Kidney Disease)",
        "Baseline EQ-5D scores (EQ5D - Visual Analog Scale)"
      ],
      "remaining_candidate_features": [
        "fasting glucose levels",
        "2-hour plasma glucose levels",
        "glycated hemoglobin (HbA1c) levels",
        "systolic blood pressure (SBP)",
        "diastolic blood pressure (DBP)",
        "use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)",
        "presence of heart failure with reduced ejection fraction (HFrEF)",
        "concomitant medications",
        "history of dialysis for acute renal failure."
      ]
    },
    "processed-gen-response": "Age, sex, fasting glucose levels, 2-hour plasma glucose levels, glycated hemoglobin (HbA1c) levels, urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), serum potassium levels, systolic blood pressure (SBP), diastolic blood pressure (DBP), use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), presence of heart failure with reduced ejection fraction (HFrEF), concomitant medications, history of dialysis for acute renal failure."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, HbA1c, eGFR, UACR, Serum Potassium, Duration of Diabetes, Use of ACEI/ARB,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Baseline UACR",
          "UACR"
        ],
        [
          "Baseline potassium",
          "Serum Potassium"
        ],
        [
          "Baseline eGFR",
          "eGFR"
        ]
      ],
      "remaining_reference_features": [
        "Baseline KDQOL-36 domain score (Effects of Kidney Disease)",
        "Baseline EQ-5D scores (EQ5D - Visual Analog Scale)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "HbA1c",
        "Duration of Diabetes",
        "Use of ACEI/ARB"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, HbA1c, eGFR, UACR, Serum Potassium, Duration of Diabetes, Use of ACEI/ARB"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Diagnosis Duration, HbA1c, eGFR, UACR, Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass Index, Potassium Level, History of Heart Failure, History of Hypertension, Use of ACEI and/or ARB.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Baseline UACR",
          "UACR"
        ],
        [
          "Baseline potassium",
          "Potassium Level"
        ],
        [
          "Baseline eGFR",
          "eGFR"
        ]
      ],
      "remaining_reference_features": [
        "Baseline KDQOL-36 domain score (Effects of Kidney Disease)",
        "Baseline EQ-5D scores (EQ5D - Visual Analog Scale)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Diabetes Diagnosis Duration",
        "HbA1c",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Body Mass Index",
        "History of Heart Failure",
        "History of Hypertension",
        "Use of ACEI and/or ARB."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Diabetes Diagnosis Duration, HbA1c, eGFR, UACR, Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass Index, Potassium Level, History of Heart Failure, History of Hypertension, Use of ACEI and/or ARB."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, duration of diabetic nephropathy, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, glycated hemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), serum potassium, use of angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), use of oral antidiabetics and/or insulin.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Baseline UACR",
          "urinary albumin-to-creatinine ratio (UACR)"
        ],
        [
          "Baseline potassium",
          "serum potassium"
        ],
        [
          "Baseline eGFR",
          "estimated glomerular filtration rate (eGFR)"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Baseline KDQOL-36 domain score (Effects of Kidney Disease)",
        "Baseline EQ-5D scores (EQ5D - Visual Analog Scale)"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "body mass index (BMI)",
        "duration of type 2 diabetes mellitus",
        "duration of diabetic nephropathy",
        "systolic blood pressure (SBP)",
        "diastolic blood pressure (DBP)",
        "fasting glucose",
        "glycated hemoglobin (HbA1c)",
        "use of angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB)",
        "use of oral antidiabetics and/or insulin."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes mellitus, duration of diabetic nephropathy, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, glycated hemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR), serum potassium, use of angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB), use of oral antidiabetics and/or insulin."
  }
}